Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation

Surudo, T; Wójcicki, Maciej; Milkiewicz, Piotr; Czuprynska, M.; Lubikowski, Jerzy; Jarosz, Konrad; Andrzejewska, J; Zeair, Samir; Śluzar, Tomasz; Syczewska, M; Butkiewicz, Jacek; Umiński, M

doi:10.1016/s0041-1345(03)00759-0

Cited by 35 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, one patient developed a postoperative hepatic artery thrombosis. Surudo et al [84] reported eight patients with prolonged PT who underwent orthotopic liver transplantation for end-stage liver cirrhosis. All subjects received a single dose of rFVIIa (mean 68.4 mg/kg) 10 min prior to the skin incision.…”

Section: Liver Transplantationmentioning

confidence: 99%

The use of recombinant factor VIIa in liver diseases

Franchini

Montagnana²,

Targher³

et al. 2008

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Recombinant activated factor VII, a bypassing hemostatic agent originally developed for the treatment of hemorrhages in hemophilic patients with inhibitors, is increasingly being employed on a compassionate use basis for the treatment of uncontrolled massive bleeding from various causes. In this review, we present the current knowledge on the use of this agent in patients with severe coagulopathy due to end-stage liver disease. In particular, the role of recombinant activated factor VII for treating gastrointestinal bleeding episodes in patients with decompensated cirrhosis or for prophylaxis before liver surgical or invasive procedures will be addressed. The pathogenesis of complex coagulopathy in chronic liver diseases and the mechanisms by which recombinant activated factor VII might improve coagulation in such patients will also be described. Given the paucity of the published data and the lack of randomized trials, there is not enough evidence to support the extensive use of recombinant activated factor VII in any of the clinical indications analyzed. In conclusion, further large randomized, controlled clinical trials are needed to better define the role of recombinant activated factor VII in the treatment of bleeding complications of liver disorders.

show abstract

Section: Liver Transplantationmentioning

confidence: 99%

The use of recombinant factor VIIa in liver diseases

Franchini

Montagnana²,

Targher³

et al. 2008

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…[19][20][21][22] Recently some authors have reported thrombotic events following therapy with rFVIIa. 23,24 Patients (trauma, liver surgery) received multiple treatments, including antibrinolytics, and the exact cause of the thromboses cannot be determined.…”

Section: Patientmentioning

confidence: 99%

FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: A report of four cases

Pavèse

Bonadona

Beaubien³

et al. 2005

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

P Pu ur rp po os se e: : During liver transplantation, excessive blood losses are correlated with increased morbidity and mortality. Blood losses are particularly high in the case of urgent liver transplantation for fulminant hepatic failure (FHF). Recombinant activated factor VII (rFVIIa) has shown promise in treating the coagulopathy of liver disease. We review our experience with the use of rFVIIa in treating the coagulopathy of FHF during urgent liver transplantation.C Cl li in ni ic ca al l f fe ea at tu ur re es s: : We report four patients with FHF who met King's College criteria for liver transplantation and in whom rFVIIa was used after conventional means for treating the associated coagulopathy had failed. In all patients, the coagulation defect was corrected by rFVIIa. However, thrombotic complications occurred in two patients (myocardial ischemia and portal vein thrombosis) and the implication of rFVIIa cannot be excluded.

show abstract

“…28 Several case reports demonstrated the use of rFVIIa to either control bleeding in patients with liver disease or for the prophylaxis of bleeding in patients with liver disease and prolonged prothrombin times undergoing invasive procedures. [29][30][31][32][33] A few studies evaluated the procoagulant effects of rFVIIa in patients with liver disease utilizing methods such as thrombin generation assays and thromboelastography. 34,35 Although much of this data is preliminary and not based on controlled clinical trials, it is likely that rFVIIa is effective in the management of coagulopathy of liver failure.…”

Section: Liver Diseasementioning

confidence: 99%

Novel Hemostatic Agents: A Focus on Recombinant Factor VIIa and Factor XIII

Young

2004

Transfus Alt Transfus Med

View full text Add to dashboard Cite

Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation

Cited by 35 publications

References 4 publications

The use of recombinant factor VIIa in liver diseases

The use of recombinant factor VIIa in liver diseases

FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: A report of four cases

Novel Hemostatic Agents: A Focus on Recombinant Factor VIIa and Factor XIII

Contact Info

Product

Resources

About